KRAS and neoplasm: Considering the final endpoint, using 454-NGS we detected a KRAS mutation in the 75.7% of adenocarcinomatous and pre-neoplastic lesions (in the 70% of PDAC cases, in the 83.3% of IPMNs and in the 66.7% of inoperable neoplasias).